Biotech Drug Report Generated Jul 14, 2026

NanoKnife

ANGO·ANGIODYNAMICS INC

BULLISH

Drug Impact Rating4/10

Trial Phase: Approved (FDA 510(k) cleared) / Commercial
Time to Market: Already FDA-cleared and commercially available (510(k) clearance December 2024); initial prostate ablation indication is launched.
Why 4/10: NanoKnife is already FDA-cleared and commercially launched; the next hard binary catalyst — a pivotal readout or label expansion decision — is not scheduled in the next ~12 months. The RELIEF BPH feasibility study (IDE approved June 2026) is early-stage. Revenue growth and Medicare reimbursement expansion are commercial drivers, not binary events, capping impactScore at 4.

Actionable Insight BULLISH

NanoKnife is a proven commercial growth engine for ANGO, posting 64.5% Q4 revenue growth after Medicare coverage activation. Watch for the commercial adoption ramp in FY2027 driven by the July 2026 Medicare coverage decision for prostate/liver IRE, and enrollment updates from the RELIEF BPH feasibility study. The stock's 9:1 analyst buy/strong-buy consensus with ~44% implied upside ($18 mean target vs ~$12.77) suggests the market hasn't fully priced in the reimbursement-driven volume inflection.

Price Chart

Loading chart...

Executive Summary

NanoKnife is AngioDynamics' irreversible electroporation (IRE) ablation system — a medical device, not a drug — that uses electrical pulses to non-thermally destroy tumors while preserving surrounding healthy tissue. It received FDA 510(k) clearance in December 2024 for prostate tissue ablation in intermediate-risk prostate cancer based on the PRESERVE pivotal trial. Named to TIME's 2025 Best Inventions list. NanoKnife is now in early commercial launch, with Medicare coverage effective July 2026. In FY2026 Q4, NanoKnife generated $11.8M in revenue (+64.5% YoY), and the company guided FY2027 net sales of $336M-$341M. The device also has an FDA IDE approval to explore treatment of benign prostatic hyperplasia (BPH) under the RELIEF feasibility study. Competition includes HIFU, cryotherapy, and other focal therapy modalities for prostate cancer.

How It Works

NanoKnife delivers high-voltage, low-energy electrical pulses through thin needles placed around a tumor. These pulses create permanent nano-sized holes in the cell membranes of targeted tissue, causing cell death — without using heat or freezing. This non-thermal approach spares nearby structures like blood vessels and nerves, making it suitable for treating tumors near sensitive anatomy (e.g., prostate, pancreas, liver).

Trial Status

The pivotal PRESERVE trial (NCT04972097, 121 patients) supported the December 2024 FDA 510(k) clearance for prostate tissue ablation in intermediate-risk prostate cancer. Two-year follow-up data presented at AUA 2026 (May 2026) showed durable oncologic control and sustained safety. A new IDE-approved feasibility study (RELIEF) evaluating NanoKnife for benign prostatic hyperplasia (BPH) began enrolling in June 2026.

The Two-Sided Case

▲ Bull Case6

NanoKnife revenue surged 64.5% YoY in FY2026 Q4 to $11.8M, with capital equipment sales up 132.5% and probe sales up 47.0%, signaling strong commercial adoption momentum (source: AngioDynamics FY2026 Q4 press release via BioSpace).

Medicare coverage (Palmetto GBA) effective July 5, 2026 for NanoKnife IRE in prostate and liver cancer, combined with Category I CPT codes, unlocks a multi-billion-dollar addressable market and broadens payer access (source: AngioDynamics investor relations).

Analyst consensus is heavily bullish: 9 of 10 analysts rate Strong Buy or Buy (7 buy, 2 strong buy, 1 hold), with a mean price target of $18 — implying ~44% upside from ~$12.77 — and a high target of $24.

Two-year PRESERVE data showed durable oncologic control and safety, strengthening the clinical evidence base for urologist adoption and competitive positioning vs. HIFU and cryotherapy (source: AngioDynamics May 2026 press release via Morningstar).

FDA IDE approval for the RELIEF BPH feasibility study (June 2026) opens a second large indication beyond prostate cancer — BPH affects millions of men and could expand NanoKnife's TAM significantly (source: Nasdaq press release).

Med Tech segment (including NanoKnife, Auryon) grew 16.7% in Q4 and now represents 47% of total revenue, with ANGO guiding $336M-$341M in FY2027 net sales (source: Seeking Alpha earnings recap).

▼ Bear Case6

NanoKnife faces established competition from HIFU (high-intensity focused ultrasound), cryotherapy, and other focal therapies for prostate cancer — modalities with longer track records and broader physician familiarity (source: urology literature review).

As a medical device, NanoKnife's commercial ramp depends on hospital capital budgets, physician training, and procedure reimbursement — growth may be lumpy and slower than the 64.5% Q4 surge suggests, especially in a tight hospital spending environment.

At ~$528M market cap and ~$12.77, ANGO's valuation already reflects positive NanoKnife momentum; the stock is near its 52-week high of $13.99, and a material miss on FY2027 guidance or slower-than-expected Medicare adoption could cause downside.

The RELIEF BPH study is only a feasibility trial — years away from FDA clearance for that indication, with no guarantee of clinical or regulatory success.

Institutional activity was mixed in Q1 2026: Bank of America more than doubled its position (+262.7%), but FMR trimmed (-26.2%), Qube Research nearly exited (-83.1%), and New York State Common Retirement Fund trimmed (-31.8%), suggesting lack of universal conviction.

Short interest was 4.52% of float as of June 15, 2026, with days-to-cover of 6.1 — elevated for a med-tech company, indicating a skeptical contingent betting against the commercial ramp thesis (source: MarketBeat short interest data).

Upcoming Catalysts

FY2027 revenue ramp from Medicare coverage (effective July 5, 2026) for NanoKnife IRE in prostate and liver cancer — watch quarterly sales disclosures for acceleration.
Enrollment initiation and early data from the RELIEF feasibility study evaluating NanoKnife for benign prostatic hyperplasia (BPH) — FDA IDE approved June 2026.
Potential label expansion into liver cancer ablation based on existing data and Medicare coverage signals.
FY2027 guidance execution: ANGO guided $336M-$341M net sales; quarterly results will show if NanoKnife revenue growth sustains its 64.5% Q4 pace.
Broader national payer coverage decisions following the Palmetto GBA Medicare local coverage determination.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ANGIODYNAMICS INC 8-K ANGO ·Originating report

Sources · 11

Hover a chip for the title

1 angiodynamics.com2 urologytimes.com3 investors.angiodynamics.com4 nasdaq.com5 time.com6 secure.businesswire.com7 investors.angiodynamics.com8 biospace.com9 seekingalpha.com10 marketbeat.com11 investors.angiodynamics.com